Valuation: Sera Prognostics, Inc.

Market Cap 7.83Cr 6.8Cr 6.36Cr 5.82Cr 11Cr 746.04Cr 11Cr 74Cr 29Cr 372.75Cr 29Cr 29Cr 1.24TCr P/E 2026 *
-3.05x
P/E 2027 * -3.57x
Enterprise Value 7.83Cr 6.8Cr 6.36Cr 5.82Cr 11Cr 746.04Cr 11Cr 74Cr 29Cr 372.75Cr 29Cr 29Cr 1.24TCr EV / Sales 2026 *
216x
EV / Sales 2027 * 29.3x
Free-Float
85.93%
Yield 2026 *
-
Yield 2027 * -
1 week-4.76%
Current month-1.96%
1 month-4.31%
3 months+10.50%
6 months-20.63%
Current year-32.20%
1 week 1.89
Extreme 1.89
2.19
1 month 1.89
Extreme 1.89
2.3
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
13.51
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Director

62,657 0.1641%
10/07/26 Free

Director

62,697 0.1642%
10/07/26 Free

Director

61,416 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.76%-27.27%-28.57% 7.83Cr
+0.06%+1.38%+15.65%+16.54% 2.35TCr
-0.64%-1.20%+39.16% - 1.55TCr
-1.62%-2.10%+13.27%-31.20% 346.89Cr
+3.86%+27.06%+36.93%+20.68% 277.58Cr
-3.04%-5.34%-28.77%-38.06% 208.15Cr
+6.11%+19.56%-13.37% - 192.73Cr
0.00%+3.70%-0.57%+6.23% 158.26Cr
-1.49%+2.00%-18.56%+1.67% 134.57Cr
+2.20%+16.48%+49.40%+92.88% 136.38Cr
Average +0.56%+3.71%+6.58%+5.02% 536.81Cr
Weighted average by Cap. +0.11%+1.46%+20.09%+10.92%

Financials

2026 *2027 *
Net sales 4L 3L 3L 3L 5L 3.45Cr 5L 34.46L 13.52L 1.73Cr 13.61L 13.31L 5.74Cr 26.75L 23.21L 21.74L 19.88L 37.54L 25Cr 38.03L 2.54Cr 99.8L 13Cr 1Cr 98.25L 42Cr
Net income -3.33Cr -2.89Cr -2.7Cr -2.47Cr -4.67Cr -316.84Cr -4.73Cr -32Cr -12Cr -158.3Cr -12Cr -12Cr -526.9Cr -3Cr -2.6Cr -2.44Cr -2.23Cr -4.21Cr -285.58Cr -4.26Cr -28Cr -11Cr -142.68Cr -11Cr -11Cr -474.91Cr
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
06/26/06 $2.000 0.00% 16,835
05/26/05 $2.000 +3.63% 57,997
04/26/04 $1.930 -8.10% 87,166
03/26/03 $2.100 +2.94% 15,272
31/26/31 $2.040 -2.86% 24,658
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.000USD
Average target price
5.500USD
Spread / Average Target
+175.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock